Neuropathology of FMR1-premutation carriers presenting with dementia and neuropsychiatric symptoms

Anke A. Dijkstra1*, Saif Haify2, Nick A. Verwey3, Niels D. Prins4,5, Esmay C. van der Toorn2, Annemieke. J.M. Rozemuller1, Marianna Bugiani1, Wilfred F.A. den Dunnen6, Peter K. Todd7,8, Nicolas Charlet-Berguerand9, Rob Willemsen2, Renate K. Hukema2,10, Jeroen J.M. Hoozemans1

1Department of Pathology, Amsterdam Neuroscience, Amsterdam University Medical Centre, location VUmc, Amsterdam, The Netherlands.
2Department of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands.
3Department of Neurology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
4Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Netherlands.
5Brain Research Center, Amsterdam, The Netherlands.
6Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.
7Department of Neurology, University of Michigan, Ann Arbor, MI, USA
8Department of Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI USA
9Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR7104, University of Strasbourg, 67400 Illkirch, France
10Rotterdam University of Applied Sciences, Department of Health Care Studies, Rotterdam, The Netherlands

* Corresponding author: Anke A. Dijkstra
a.dijkstra@amsterdamumc.nl
+31204444032

Running title: Neuropathology of FMR1-premutation cases

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

https://mc.manuscriptcentral.com/braincom
Abstract

CGG repeat expansions within the premutation range (55-200) of the *FMR1* gene can lead to Fragile-X associated tremor/ataxia syndrome and Fragile-X associated neuropsychiatric disorders. These CGG repeats are translated into a toxic polyglycine-containing protein, FMRpolyG. Pathology of Fragile-X associated tremor/ataxia syndrome and Fragile-X associated neuropsychiatric disorders comprise FMRpolyG- and p62-positive intranuclear inclusions. Diagnosing a *FMR1*-premutation carrier remains challenging, as the clinical features overlap with other neurodegenerative diseases. Here, we describe two male cases with Fragile-X associated neuropsychiatric disorders related symptoms and mild movement disturbances and novel pathological features that can attribute to the variable phenotype. Macroscopically, both donors did not show characteristic white matter lesions on MRI, however, vascular infarcts in cortical- and subcortical regions were identified. Immunohistochemistry analyses revealed a high number of FMRpolyG intranuclear inclusions throughout the brain, which were also positive for p62. Importantly, we identified a novel pathological vascular phenotype with inclusions present in pericytes and endothelial cells. Although these results need to be confirmed in more cases, we propose that these vascular lesions in the brain could contribute to the complex symptomology of *FMR1*-premutation carriers. Overall, our report suggests that Fragile-X associated tremor/ataxia syndrome and Fragile-X associated neuropsychiatric disorders may present diverse clinical involvements resembling other types of dementia, and in the absence of genetic testing, FMRpolyG can be used post-mortem to identify premutation carriers.

Keywords: neuropathology, FXTAS, FMR1-premutation, nuclear inclusions, FXAND

Abbreviations:

FLAIR: fluid-attenuated inversion recovery; FXAND: Fragile X-associated neuropsychiatric disorders; FXPOI: Fragile X-associated primary ovarian insufficiency; FXTAS: Fragile X-associated tremor/ataxia syndrome; H&E: Hematoxylin and eosin; MCP: middle cerebral peduncle; NBB: Netherlands Brain Bank; PBS: phosphate buffer saline; RAN: repeat-associated non-AUG-initiated; SCA3: spinocerebellar ataxia type 3; SWI: susceptibility weighted imaging

https://mc.manuscriptcentral.com/braincom
Introduction

The fragile X mental retardation 1 (FMR1) gene contains a CGG dynamic trinucleotide repeat sequence. Within the general population, this number of CGG repeats is present under 55 repeats (Hagerman and Hagerman, 2015). Expansions of the repeat sequence to more than 200 CGG repeats result in the absence of the FMR1 protein, and in the fragile X syndrome (Murray et al., 1997). Smaller expansions, from 55 to 200 CGG repeats, are in the premutation range (Brouwer et al., 2009) and can lead to Fragile-X associated diseases, including the neurodegenerative diseases Fragile X-associated tremor/ataxia syndrome (FXTAS) (Berry-Kravis et al., 2007a), and the Fragile X-associated neuropsychiatric disorders (FXAND) (Hagerman et al., 2018). CGG-repeats in the premutation range are transcribed and translated into a toxic polyglycine-containing protein, named FMRpolyG protein (Todd et al., 2013). FMRpolyG is considered to play a major role in the pathogenesis of FXTAS (Sellier et al., 2017; Boivin et al., 2018).

The FXTAS phenotype is found in 30% of male carriers and 11-18% of female carriers of the FMR1-premutation and is characterized primarily by intention tremors and cerebellar gait ataxia, and in severe cases accompanied by executive function, memory deficits, and Parkinsonism (Jacquemont et al., 2004; Leehey et al., 2016; Robertson et al., 2016). The onset of the motor symptoms may present after 50 years of age, with longer expansions correlating with an earlier onset and more severe disease (Tassone et al., 2007). However, additional clinical features have been recently described in premutation carriers that include anxiety and depression, which has led to the recent identification of FXAND, encompassing a large group of premutation carriers presented with neuropsychiatric symptoms (Hagerman et al., 2018). Consequently, diagnosing a FMR1-premutation carrier remains challenging, as the clinical features may overlap with other neurodegenerative diseases (Grigsby et al., 2007; Seritan et al., 2008). A genetic screening for CGG expansion can provide the conclusive answer, especially when a grandchild or child is diagnosed with a full mutation leading to the Fragile X syndrome (Young, 1993).

The pathology of an FMR1-premutation includes p62-positive and mostly solitary, spherical intranuclear inclusions, present in both neurons and astrocytes and found in broad distribution throughout the brain and brainstem (Greco et al., 2006; Tassone et al., 2012). Post-mortem studies in FXTAS donors also revealed cerebellar and cerebral white matter abnormalities with inclusions in astrocytes, particularly evident in sub-cortical cerebral white matter (Greco et al.,
2006). This is consistent with MRI studies that reveal global brain atrophy and white matter signal changes with characteristic feature middle cerebral peduncle (MCP) presents in about 40% of the FXTAS patients (Famula et al., 2018). Here, we describe novel pathological features of two cases with a FMR1-premutation and a clinical profile of FXAND with mild movement impairments. Our study supports recent studies showing that testing for FMRpolyG immunoreactivity can confirm presence of the FMR1-premutation (Todd et al., 2013; Krans et al., 2019).
Materials and methods

Magnetic Resonance Imaging

Donors were scanned on a 3T whole-body magnetic resonance system (General Electric, Milwaukee, WI). The protocol included a 3D T1-weighted fast spoiled gradient echo sequence for volumetric measurements and for donor two, a 3D T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence for white matter lesion segmentation.

Post-mortem tissue

Post-mortem tissue was obtained through the Netherlands Brain Bank (NBB) and the department of Pathology, University Medical Center Groningen, The Netherlands. Tissue of a spinocerebellar ataxia donor type 3 (SCA3) was obtained through the NBB and used as a negative control for FMRpolyG. Tissue was fixed in 4% PFA for 4 weeks and dissected in 24 diagnostic regions. Sections of 8 μm of each region were cut and stained using Hematoxylin and Eosin (H&E) and Perls staining for iron deposits. Donors were routinely immunostained for amyloid-beta (1:800; mouse, clone IC16 kind gift of Prof Dr Korth, Heinrich Heine University, Düsseldorf, Germany), tau (1:800; mouse, clone AT8, Thermo Fisher Scientific, MA, USA), alpha-synuclein (1:1000; mouse, Zymed; Thermo Fisher Scientific, Bleiswijk, The Netherlands), TDP-43 (pTDP43, 1:8000; mouse, clone 11-9, Cosmo Bio, Japan) and polyQ (1:800; mouse, clone 5TF1-1C2, Merck Millipore, Burlington, USA).

Immunohistochemical procedures

Sections were deparaffinized and then incubated in 0.3% H₂O₂ in phosphate buffer saline (PBS; pH 7.4) for 30 minutes. Sections were then washed with PBS (3x5 minutes) and antigen retrieval was performed in citrate buffer (pH 6.0) using an autoclave (121°C for 5 minutes). After washing, sections were incubated in primary antibody (p62, 1:1000; mouse, clone 3/P62 lck ligand, BD Transduction Laboratories, San Jose, CA, USA) FMRpolyG (NTF1), 1:200; Rabbit, antibody developed by Peter Todd; FMRpolyG (1C5), 1:500; mouse developed by Nicolas Charlet-Berguerand) for 1 hour at room temperature. After washing, sections were incubated with HRP-labelled Envision (K5007; DAKO, Glostrup, Denmark), washed and visualization of immunostaining was seen with chromogen 3,3'-diaminobenzidine (DAB; K5007; DAKO). Finally, sections were counterstained with hematoxylin, dehydrated, and...
cover slipped with Quick-D (Klinipath, Duiven, The Netherlands). Negative controls were included by omitting the primary antibody and showed no immunoreactivity.

**Double-labelling immunofluorescence**

For double-immunofluorescence, sections were incubated for one hour with a combination of primary antibodies; p62 (1:1000) and FMRpolyG (NTF1) (1:200). Subsequently sections were incubated with fluorescent probed secondary antibodies 1:250 (1 hour); Goat Anti-Rabbit-594 (Invitrogen, Carlsbad, CA, USA), and Goat Anti-Mouse 488 (Life Technologies, Carlsbad, CA, USA). Auto-fluorescence was blocked with 0.2% Sudan Black for 5 minutes at room temperature and mounted with DAPI Fluoromount G (Southern Biotech, AL, USA).

**Statistical Analysis**

No analyses were performed

**Data availability**

Data are available upon request.
Results

Clinical profile

Donor one: At age 57, the patient complained about pain in his legs and subsequently polyneuropathy was diagnosed. At 59, he was seen again at the neurological outpatient clinic due to a minor stroke. Besides the sub-acute stroke related neurological signs, the patient complained about progressive cognitive problems (memory and slowness). Additionally, behavioral changes (apathic and passive) were mentioned. The patient spent whole days just listening to music and was easily agitated and not cooperative. Neurological examination showed several signs of parkinsonism. Initially, Vascular Dementia/Parkinsonism (VAD) or Parkinson Disease (PD) were mentioned as diagnosis. The MRI showed mild vascular changes, and VAD seemed unlikely. As disease progressed, other symptoms became more apparent such as executive problems, increased cognitive decline but also significant bradyphrenia. Clinically, the patient was demented and atypical Alzheimer’s disease (AD) and Fronto-temporal dementia (FTD) were added to the differential diagnosis. Biomarkers did not provide any indication for AD. Additionally, an FDG-PET scan was performed showing a pattern which partially suited corticobasal degeneration (CBD) or less likely progressive supranuclear palsy. However, CBD or PSP were clinically less evident, since dementia with significant frontal characteristics was pronounced. The patient showed increased psychiatric problems, including aggressiveness towards partner, apathy, and compulsive behavior. Due to an acute unsustainable situation at home, the patient was taken into a psychiatric hospital where he committed suicide at age 62. After autopsy, the donor presented intranuclear inclusion pathology. FMRpolyG immunohistochemistry was positive and subsequent genetic testing revealed a 107 CGG repeat within the FMR1 gene.

Donor two: At age 43, this patient came to the memory clinic with memory problems and aphasia, while his partner noted that he became aggressive towards her. He showed signs of social anxiety and suffered from chronic depression. He was initially diagnosed with Korsakoff’s syndrome based on earlier excessive alcohol consumption and the early onset of the symptoms. At age 51, he complained of memory loss and concentration problems and character changes. At age 53 he suffered from cardiac palpitations and cramps in his fingers, but no cause was found. He had visual hallucinations, in which he saw persons and felt drawn towards the cemetery. A year later he experienced a change in gait, and dragged his feet. At age 55, he had a major stroke in the right occipital region, reporting loss of strength and coordination.
in his left arm and leg, followed by a spontaneous recovery. A year later he suffered from falling and increased bradykinesia. He had a light tremor in both hands, started snoring and developed sleep apnea. Around this time, his grandchildren were born and diagnosed with Fragile X syndrome. Genetic testing revealed a 77 CGG repeat in the FMR1 gene, and his initial diagnosis of Korsakov’s syndrome was retracted. Neuropsychological tests showed cognition disorders concerning short- and long-term memory, feelings of depression, fear, paranoia and anger, agitation, loss of concentration and initiative, and difficulties with divided attention. Over the years, his symptoms worsened, with increasing cognitive problems, ataxia, tremor, hallucinations and dependency on others for his personal care and hygiene. He was well aware of his deterioration and started a euthanasia trajectory and passed away at age 65. The disease course of both donors is summarized in Fig. 1A.

**MRI findings**

Both donors showed general athrophy throughout the cortex (Fig. 1B,C,F,G) and dilation of ventricles (Fig. 1C,E,G). White matter intensity changes were observed around the ventricles, and small lesions were observed (Fig. 1B,C,D,E,M one (Fig. 1E) and donor two, (Fig. 1K). While donor two suffered from a stroke 10 years prior to his passing, a susceptibility weighted imaging (SWI) for donor two revealed no large vascular damage (Fig. 1L). No obvious thinning of the corpus callosum was seen (Fig. 1M). Overall, both donors revealed mild abnormalities on MRI including periventricular white matter intensities and mild global athrophy fitting with several neurodegenerative diseases.

**P62-Inclusion pathology**

Intranuclear p62-positive inclusions were found in all brain structures, similar as reported before for FXTAS (Greco et al., 2006). Cortical structures such as the frontal cortex showed inclusions in neurons and astrocytes in grey and white matter (Fig. 2A-D). Hippocampus showed many inclusions in CA and dentate gyrus granular cells (Fig. 2E,F). In the cerebellum, inclusions were observed in the white matter and granular cell layer, and in most of the Bergmann glia but not in the Purkinje cells (Fig. 2G,H). The substantia nigra (SN) showed inclusions in astrocytes and dopaminergic neurons (Fig. 2I). Similar to earlier reported findings in FXTAS, inclusions were also found in the ependymal layer (Fig. 2J) and choroid plexus (Fig. 2K). Additional findings include the presence of inclusions in the extra-axial part of nerve 3, but not intra-axial (Fig. 2L).
Vascular pathology

Both donors showed vascular lesions such as lacunae and strokes throughout the brain. In the H&E staining, brown iron deposits were appreciated (Fig. 3A,E). Perls staining showed that the disrupted vasculature resulted in iron deposits, found throughout the cortex and hippocampus in normal age-related amounts (Fig. 3B,F), and an abnormal increased amount of iron deposits in the ventral region of the SN (Fig. 3C,G). Small p62-positive intranuclear inclusions were observed in the endothelial cells of the blood vessels, as well as in the pericytes (Fig. 3D, H). An overview of p62-inclusions in different cell types and iron deposits visualized by Perls staining is provided per region in Table 1.

FMRpolyG pathology

FMRpolyG was detected in all regions of the brain. FMRpolyG intranuclear inclusions are shown in the frontal cortex (Fig. 4A), the hippocampus (Fig. 4B), the astrocytes in SN (Fig. 4C) and in the Bergmann glia in the cerebellum (Fig. 4D). FMRpolyG positivity was also observed in the vasculature. Double-immunofluorescence for FMRpolyG and p62 showed that FMRpolyG protein co-localizes with p62 inclusions in the cerebellum (Fig. 4E-H), where an occasional p62-inclusion did not show FMRpolyG positivity. As a negative control, no immunoreactivity of FMRpolyG was observed in a case of spinocerebellar ataxia 3 (SCA3) (Fig. 4I-L), confirming the specificity of our antibodies for the FMR1-premutation translated product, FMRpolyG.
Discussion

Here, we report two cases with dementia and psychiatric symptoms that were diagnosed as FMR1-premutation carriers either post-mortem or in advanced disease state. While initial symptoms suggested dementia, both donors showed mild movement disturbances during the progression of the disease. MRI did not reveal the characteristic FXTAS-related imaging profile, which, in combination with the symptoms, posed a challenge for the attending clinicians to diagnose the patients as potential FMR1-premutation carriers. Interestingly, both donors experienced cerebrovascular accidents which could be explained by the post-mortem findings of FMRpolyG inclusions in the endothelial cells and pericytes. We propose that these brain vascular lesions may contribute to the complex symptomology of FMR1-premutation carriers.

Clinical findings

The clinical phenotype for FXTAS has been described in detail, where movement symptoms are the most prominent features of the disease (Hagerman, 2013; Leehey et al., 2016; Robertson et al., 2016). However, the two FMR1-premutation individuals described here exhibited only mild movement symptoms such as rigidity and bradykinesia, and showed predominantly psychiatric problems, matching the recent description of FXAND (Hagerman et al., 2018). Interestingly, donor one experienced polyneuropathy as one of the first symptoms, which can be a prevalent sign in FMR1-premutation carriers with FXTAS presentation (Berry-Kravis et al., 2007b; Hagerman et al., 2007). Of clinical importance, the two donors did not show the typical MCP imaging feature of FXTAS, however, they did show mild atrophy, similar to other dementias. This work highlights the challenge for clinicians to diagnose FMR1-premutation carriers, and stresses the importance of genetic screening for CGG repeats within FMR1 for suspected dementia with behavioral features.

Inclusion pathology

The p62-inclusion pathology of the two cases described here show a similar distribution pattern as described in FXTAS (Greco et al., 2006; Tassone et al., 2004). However, we describe here an additional feature with inclusions present in the endothelial cells and pericytes that can compromise vascular function. As both donors also suffered from multiple vascular incidents in the brain, this suggests that apart from cellular dysfunction, problems in the brain vasculature can contribute to the FMR1-premutation phenotype where infarcts or transient ischemic attacks can disrupt blood supply. Consistent with our hypothesis, a high incidence of cardiac
abnormalities and cerebrovascular disease have been observed in FXTAS donors (Hall et al., 2005; Hamlin et al., 2012), which could be linked to a decline in vascular integrity due to inclusion pathology. In addition, inclusions have been observed in cardiomyocytes (Hunsaker et al., 2011), suggesting that the peripheral vasculature could also be compromised. Furthermore, inclusions were found in the extra-axial part of the nerve sheet, it is possible that the neuropathy can be explained by nerve involvement in the sensory nerves, which has to be studied in future autopsies of carriers.

Our work also confirms that the inclusion pathology in carriers of the \textit{FMR1} premutation can be visualized with antibodies directed against FMRpolyG (Krans et al., 2019), with almost all p62-positive inclusions also positive for FMRpolyG. However, we noted that the dopaminergic neurons of the SN showed multiple p62-positive inclusions in one cell that were not positive for FMRpolyG. These inclusions are most likely Marinesco bodies (Beach et al., 2004), which are age-related nuclear inclusions restricted to the SN. FMRpolyG labeling is specific to the protein translated from the \textit{FMR1}-premutation, and is not present in the polyQ aggregates found in SCA3. Importantly, we propose that FMRpolyG antibodies can be used as diagnostic tools to identify \textit{FMR1}-premutation carriers post-mortem, notably in large retrospective brain bank cohorts.

**Acknowledgements**

The authors would like to thank the Netherlands Brain Bank for providing tissue and Irene van Dijken for her input on the immunofluorescence experiments.

**Funding**

This work was funded by Memorabel Zorgonderzoek Nederland, gebied Medische wetenschappen (733050507). Peter Todd was supported by the National Institutions of Health (R01NS086810, R01NS099280) and the Veterans affairs (BLRD BX004842)

**Competing interests**

The authors report no competing interests.
References

Beach, T.G., et al., 2004. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurol. 63, 329-37.

Berry-Kravis, E., et al., 2007a. Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Movement Disorders. 22, 2018-2030.

Berry-Kravis, E., et al., 2007b. Neuropathic features in fragile X premutation carriers. American Journal of Medical Genetics Part A. 143A, 19-26.

Boivin, M., et al., 2018. Potential pathogenic mechanisms underlying Fragile X Tremor Ataxia Syndrome: RAN translation and/or RNA gain-of-function? Eur J Med Genet. 61, 674-679.

Brouwer, J.R., Willemsen, R., Oostra, B.A., 2009. The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet. 150B, 782-798.

Famula, J.L., et al., 2018. Presence of Middle Cerebellar Peduncle Sign in FMR1 Premutation Carriers Without Tremor and Ataxia. Front Neurol. 9, 695.

Greco, C.M., et al., 2006. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain. 129, 243-255.

Grigsby, J., et al., 2007. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Movement Disorders. 22, 645-650.

Hagerman, P., 2013. Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms. Acta Neuropathol. 126, 1-19.

Hagerman, P.J., Hagerman, R.J., 2015. Fragile X-associated tremor/ataxia syndrome. Ann N Y Acad Sci. 1338, 58-70.

Hagerman, R.J., et al., 2007. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A. 143A, 2256-2260.

Hagerman, R.J., et al., 2018. Fragile X-Associated Neuropsychiatric Disorders (FXAND). Front Psychiatry. 9, 564.

Hall, D.A., et al., 2005. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology. 65, 299-301.

Hamlin, A.A., et al., 2012. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A. 158A, 1304-9.

Hunsaker, M.R., et al., 2011. Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol. 122, 467-79.
Jacquemont, S., et al., 2004. Penetrance of the fragile x-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 291, 460-9.

Krans, A., et al., 2019. Neuropathology of RAN translation proteins in fragile X-associated tremor/ataxia syndrome. Acta Neuropathol Commun. 7, 152.

Leehey, M.A., et al., 2016. Clinical Neurological Phenotype of FXTAS. In: FXTAS, FXPOI, and Other Premutation Disorders. Vol., F. Tassone, D.A. Hall, ed.^eds. Springer International Publishing, Cham, pp. 1-24.

Murray, J., et al., 1997. Screening for fragile X syndrome: information needs for health planners. J Med Screen. 4, 60-94.

Robertson, E.E., et al., 2016. Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders. Clin Neuropsychol. 30, 849-900.

Sellier, C., et al., 2017. Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome. Neuron. 93, 331-347.

Seritan, A.L., et al., 2008. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): Comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 147B, 1138-1144.

Tassone, F., et al., 2004. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet. 41, E43.

Tassone, F., et al., 2007. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet. 144B, 566-569.

Tassone, F., et al., 2012. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav. 11, 577-85.

Todd, P.K., et al., 2013. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron. 78, 440-55.

Young, I.D., 1993. Diagnosing Fragile-X Syndrome. Lancet. 342, 1004-1005.

Table legend

Table 1. Distribution and burden of inclusion pathology and iron deposits throughout the brain of donor 1 and 2.
Figure Legends

Figure 1. *Clinical course and imaging results of donor one and two.* Clinical course (A) shows moment in time of MRI. General mild atrophy is observed (B,F). Ventricles are slightly dilated and donor one shows periventricular white matter lesions (C), donor two shows an increased signal due to an infarct (G). Slight cerebellar atrophy can be seen in both donors (D,E,H,I). Enlargement of the fourth ventricle, but no FXTAS-characteristic MCP sign can be seen. T2-FLAIR of donor two does not show increased insular and MCP signal intensities (J,K), no abnormalities in vasculature (K), and no thinning of the corpus callosum (M). CVA: cerebrovascular accident; PNP: polyneuropathy; VD: vascular dementia; PD: Parkinson’s disease; AD: Alzheimer’s disease; CBD: corticobasal degeneration; FTD: frontotemporal dementia; PSP: progressive supranuclear palsy.

Figure 2. *p62-pathology in donor two.* Abundant p62-positive nuclear inclusions in the frontal cortex grey matter (A,B) and white matter (C,D). The hippocampus shows nuclear inclusions in the CA4 neuron (white arrowhead) and the dentate gyrus (E,F). In the cerebellum, inclusions are seen in the white matter and granular layer (G,H). No inclusions were seen in the Purkinje cells, whereas most Bergmann glia showed inclusions (H). Pathology was also seen in the dopaminergic neurons (white arrowhead) and astrocytes (black arrowhead) in the substantia nigra (I), ependymal (J), extra-axial cells of the 3rd nerve (K), and choroid plexus cells (L). Scale bar A is 50 μm, Scale bar B,D,F,H,I-L is 10 μm, scale bar C,E,G is 100 μm.

Figure 3. *Vascular pathology of donor one and two.* Brown iron-like deposits are seen in both donors (A,E), which stain blue in a Perls staining (B,F). Both donors showed abnormal increased iron deposits in the ventral part of the substantia nigra (C,G). Throughout the brain, inclusions were seen in the endothelial cells (black arrowhead) and the pericytes (white arrowhead) (D,H). Scale bar A,B,D,E,F,H is 10 μm, scale bar C,G is 0.5 cm.

Figure 4. *FMRpolyG-positivity in donor two.* FMRpolyG (1C5) positive-inclusions are seen in the frontal cortex (A), hippocampus (B), substantia nigra (C), and cerebellum (D). Inclusions are indicated with white arrowheads. Co-localization of p62 and FMRpolyG (NTF1) immunopositivity in the Bergmann glia of the cerebellum in donor two and spinocerebellar ataxia 3 (SCA3) donor. Bergmann glia shown with DAPI (E,I) showed inclusions with p62 (F,J), and FMRpolyG (G,K). Co-localization of the immunopositivity shows overlap in FXAND (H) and not in SCA3 (L). Scale bar is 10 μm.

https://mc.manuscriptcentral.com/braincom
Figure 1. Clinical course and imaging results of donor one and two. Clinical course (A) shows moment in time of MRI. General mild atrophy is observed (B,F). Ventricles are slightly dilated and donor one shows periventricular white matter lesions (C), donor two shows an increased signal due to an infarct (G). Slight cerebellar atrophy can be seen in both donors (D,E,H,I). Enlargement of the fourth ventricle, but no FXTAS-characteristic MCP sign can be seen. T2-FLAIR of donor two does not show increased insular and MCP signal intensities (J,K), no abnormalities in vasculature (K), and no thinning of the corpus callosum (M).

CVA: cerebrovascular accident; PNP: polyneuropathy; VD: vascular dementia; PD: Parkinson’s disease; AD: Alzheimer's disease; CBD: corticobasal degeneration; FTD: frontotemporal dementia; PSP: progressive supranuclear palsy.

206x242mm (300 x 300 DPI)
Figure 2. p62-pathology in donor two. Abundant p62-positive nuclear inclusions in the frontal cortex grey matter (A,B) and white matter (C,D). The hippocampus shows nuclear inclusions in the CA4 neuron (white arrowhead) and the dentate gyrus (E,F). In the cerebellum, inclusions are seen in the white matter and granular layer (G,H). No inclusions were seen in the Purkinje cells, whereas most Bergmann glia showed inclusions (H). Pathology was also seen in the dopaminergic neurons (white arrowhead) and astrocytes (black arrowhead) in the substantia nigra (I), ependymal (J), extra-axial cells of the 3rd nerve (K), and choroid plexus cells (L). Scale bar A is 50 μm, Scale bar B,D,F,H,I-L is 10 μm, scale bar C,E,G is 100 μm.
Figure 3. Vascular pathology of donor one and two. Brown iron-like deposits are seen in both donors (A,E), which stain blue in a Perls staining (B,F). Both donors showed abnormal increased iron deposits in the ventral part of the substantia nigra (C,G). Throughout the brain, inclusions were seen in the endothelial cells (black arrowhead) and the pericytes (white arrowhead) (D,H). Scale bar A,B,D,E,F,H is 10 μm, scale bar C,G is 0.5 cm.
Figure 4. FMRpolyG-positivity in donor two. FMRpolyG (1C5) positive-inclusions are seen in the frontal cortex (A), hippocampus (B), substantia nigra (C), and cerebellum (D). Inclusions are indicated with white arrowheads. Co-localization of p62 and FMRpolyG (NTF1) immunopositivity in the Bergmann glia of the cerebellum in donor two and spinocerebellar ataxia 3 (SCA3) donor. Bergmann glia shown with DAPI (A,E) showed inclusions with p62 (B,F), and FMRpolyG (C,G). Co-localization of the immunopositivity shows overlap in FXAND (D) and not in SCA3 (H). Scale bar is 10 μm.
Table 1. Distribution and burden of inclusion pathology and iron deposits throughout the brain of donor 1 and 2.

| Area         | Region                  | Donor 1 | Donor 2 |
|--------------|-------------------------|---------|---------|
|              | p62                     | neuron  | astrocytes | vessel | Perls | p62           | neuron  | astrocytes | vessel | Perls |
| Cortex       | Frontal cortex          | •••     | •••       | •       | •     | •••           | •••     | •••       | •       | •     |
|              | Temporal cortex         | •••     | •••       | •       | •     | •••           | •••     | •••       | •       | •     |
|              | Parietal                | •       | •         | •       | •     | •••           | •••     | •         | •       | •     |
|              | Occipital cortex        | ••       | •         | •       | •     | •••           | •••     | •         | •       | •     |
|              | Insular cortex          | ••       | •         | •       | •     | •••           | •••     | •         | •       | •     |
| Limbic       | Amygdala                | ••       | •         | •       | •     | •••           | •••     | •         | •       | •     |
|              | Hippocampus             | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
|              | Entorhinal cortex       | ••       | •         | •       | •     | •••           | •••     | •         | •       | •     |
| Subcortical  | Putamen                 | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
|              | Globus Pallidus         | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
|              | Caudatus                | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
|              | Thalamus                | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
| Cerebellum   | Dentate nucleus         | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
|              | Folia                   | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
| Brainstem    | Substantia Nigra        | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |
|              | Locus ceruleus          | •••     | •••       | •••     | •••   | •••           | •••     | •••       | •••     | •••   |

n/a = not available. P62: -= not present, •=few inclusions present, ••=moderate amount of inclusions present, •••=abundant amount of inclusion present. Perls: -= not present, •=few iron deposits, ••=moderate amount of iron deposits, •••=abundant amount of iron deposits.
Clinical phenotype *FMR1*-premutation carriers

| Movement symptoms | Psychiatric symptoms |
|-------------------|---------------------|
| Fragile-X associated tremor/ataxia syndrome | Fragile-X associated neuropsychiatric disorders |

Two donors with prominent psychiatric features

Inclusions are positive for FMRpolyG

Novel feature of vascular inclusions

Graphical abstract
FMRI-premutation carriers can present clinically with a range of symptoms, including neuropsychiatric symptoms. Pathologically, the nuclear inclusions are positive for FMRpolyG and in the donors discussed here, also present in the vasculature. This has not been described before and this finding possibly contributes to the complex phenotype.